Investigating genetic factors that affect treatment choices for lethal prostate cancer
Genetic and genomic determinants of homologous recombination repair deficiency as treatment selection markers for lethal prostate cancer
This study is looking at how certain genetic changes in men with advanced prostate cancer can help doctors choose the best treatments for them, making care more personalized and effective.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10771150 on NIH RePORTER |
What this research studies
This research focuses on understanding how genetic mutations related to homologous recombination repair deficiency (HRD) influence treatment options for men with metastatic castration-resistant prostate cancer (mCRPC). By analyzing the genetic profiles of patients, the study aims to categorize them based on their HRD status, which could help predict their response to various therapies, including hormonal treatments and chemotherapy. The approach involves a patient-centered methodology that seeks to identify specific genetic markers that can guide treatment decisions, potentially leading to more effective and personalized care.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with metastatic castration-resistant prostate cancer who may have genetic mutations affecting homologous recombination repair.
Not a fit: Patients without metastatic castration-resistant prostate cancer or those whose cancer is not influenced by homologous recombination repair deficiency may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more tailored treatment strategies for patients with lethal prostate cancer, improving their chances of response to therapies.
How similar studies have performed: Previous studies have shown promising results in using genetic markers to predict treatment responses in similar patient populations, suggesting a potential for success in this approach.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Luo, Jun — Johns Hopkins University
- Study coordinator: Luo, Jun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.